SPY411.49+2.97 0.73%
DIA337.86+2.73 0.81%
IXIC13,900.19+70.88 0.51%

BRIEF-Arch Biopartners Receives Health Canada Authorization To Amend Phase Ii Trial Protocol For Lsalt Peptide

· 03/16/2021 08:57
BRIEF-Arch Biopartners Receives Health Canada Authorization To Amend Phase Ii Trial Protocol For Lsalt Peptide

- Arch Biopartners Inc ARCH.V:

  • ARCH BIOPARTNERS RECEIVES HEALTH CANADA AUTHORIZATION TO AMEND PHASE II TRIAL PROTOCOL FOR LSALT PEPTIDE

Source text for Eikon: ID:nGNX5nldkk

Further company coverage: ARCH.V


((Reuters.Briefs@thomsonreuters.com;))